ENGN
HealthcareenGene Holdings Inc.
$8.73
$-0.12 (-1.36%)
Jan 5, 2026
Price History (1Y)
Analysis
enGene Holdings Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $584.78 million. The company has 81 employees and falls under the industry of Biotechnology. The financial health of enGene Holdings Inc. is characterized by negative profitability, as indicated by gross margin, operating margin, and profit margin all being at 0.0%. Returns on equity and assets are also negative at -53.3% and -28.9%, respectively. The company's balance sheet shows $31.80 million in debt against $193.74 million in cash, resulting in a debt-to-equity ratio of 18.96. The valuation context for enGene Holdings Inc. includes a forward P/E ratio of -4.32 and an EV/EBITDA ratio of -3.51. The company does not pay dividends with a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About enGene Holdings Inc.
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada.
Visit website →Key Statistics
- Market Cap
- $584.78M
- P/E Ratio
- N/A
- 52-Week High
- $11.14
- 52-Week Low
- $2.65
- Avg Volume
- 1.29M
- Beta
- -0.28
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- Canada
- Employees
- 81